Testosterone treatment of clinical hypogonadism in patients with HIV/AIDS

International Journal of STD and AIDS

Volumn 8, Issue 9, 1997, Pages 537-545

  Rabkin, Judith G ^a,b   Rabkin, Richard ^a   Wagner, Glenn J ^a  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

HIV; Hypogonadism; Testosterone; Treatment

Indexed keywords

TESTOSTERONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNITY; CLINICAL FEATURE; ENERGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOGONADISM; LIBIDO; MANIA; MOOD; MUSCLE MASS; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING; VIRUS INFECTION; WEIGHT REDUCTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV INFECTIONS; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 0030855772     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462971920703     Document Type: Review

References (53)

1. Poretsky L, Can S, Zumoff B. Testicular dysfunction in human immunodeficiency virus-infected men. Metabolism 1995;44:946-53
2. Laudat A, Blum L, Guechot J, et al. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: relationships with the CD4 cell counts. Eur J Endocrinol 1995;133:418-24
3. Engelson E, Rabkin JG, Rabkin R, Kotler DP. Effects of testosterone on body composition. J Acquir Immune Defic Synd Hum Retrovirol 1996;11:510-11
4. Rabkin JG, Rabkin R. Testosterone replacement therapy for HIV-infected men. The AIDS Reader 1995;5:136-44
5. Rabkin JG, Wagner G, Rabkin R. Treatment of depression in HIV+ men: literature review and report of an ongoing study of testosterone replacement therapy. Ann Behav Med 1996;18:24-9
6. Wyle FA, Kent JR. Immunosuppression by sex asteroid hormones. Clin Exp Immunol 1977;27:407-15
7. Mendelsohn J, Multer MM, Bernheim JL. Inhibition of human lymphocyte stimulation by steroid hormones: cytokinetic mechanisms. Clin Exp Immunol 1977;27:127-34
8. Grossman CJ. Regulation of the immune system by sex steroids. Endocr Rev 1984;5:435-55
9. Raveche ES, Steinberg AD. Sex hormones in autoimmunity. In: Berczi I, ed. Pituitary Function and Immunity. Boca Raton: CRC Press, 1986
10. Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol 1985;271:11-18
11. Calabrese LH, Kleiner S, Barna B, at al. The effects of anabolic steroids and strength training on the human immune response. Med Sci Sports Exerc 1989;21:386-92
12. Safai B, Dias B. Kaposi's sarcoma and cloacogenic carcinoma associated with AIDS. In: Broder S, Merigan T, Bolognesi D, eds. Textbook of AIDS Medicine. Baltimore: Williams and Wilkins, 1994:401-14
13. Christeff N, Gharakhanian S, Thobie N, et al. Effect of interferon alpha A2 on serum androgen in HIV+ men with Kaposi's sarcoma. International Conference on AIDS, 7-12 August 1994, Japan (Abstract No. PB120)
14. Christeff N, Winter C, Gharakhanian S, et al. Differences in androgens of HIV-positive patients with and without Kaposi's sarcoma. J Clin Path 1995;48:513-18
15. Jacobson MA, Fusaro RE, Galmarini M, et al. Decreased serum dehydroepiandrosterone is associated with an increased progression of HIV infection in men with CD4 cell counts 200-499. J Infect Dis 1991;164:864-8
16. Rosenthal E, Formanto JL, Giudicelli J, et al. DHEA: estrogen, progesterone and androgen and their receptors in epidemic Kaposi's sarcoma. International Conference on AIDS, Berlin, 1993 (Abstract No. PO-B-12-1605)
17. Klauke S, Schoefer H, Althoff P, et al. Sex hormones as a cofactor in the pathogenesis of epidemic Kaposi's sarcoma. AIDS 1995;9:1295-6
18. Harris PJ. Intramuscular administration of human chorionic gonadotropins to treat Kaposi's sarcoma. AIDS Patient Care STDs 1996;10:154-61
19. Gill PS, Lunardi-Iskandar Y, Louie S, et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996;335:1261-9
20. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335:123-8
21. Beral V, Bull D, Jaffe H, et al. Is risk of Kaposi's sarcoma in AIDS patients in Britain increased if sexual partners came from the United States or Africa? BMJ 1991;302:624-5
22. Chang Y, Cesarman E, Pessin M, et al. Identification of herpes-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9
23. Jackson JA, Waxman J, Spiekerman AM. Prostatic complications of testosterone replacement therapy. Arch Int Med 1989;149:2365-6
24. Cunningham GR. Overview of androgens on the normal and abnormal prostate. In: Bhasin S, Gabelnick H, Spieler J, Swerdloff R, Wang C, Kelly C, eds. Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley, 1996:79-93
25. Vermeulen A. Androgens and male senescence. In: Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. New York: Springer-Verlag, 1990:261-76
26. Schroder FH. Does testosterone treatment increase the risk or induction of progression of occult cancer of the prostate? In: Bhasin S, Gabelnick H, Spieler J, Swerdloff R, Wang C, Kelly C, eds. Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley, 1996:137-42
27. Collins MMcN, Barry MJ. Controversies in prostate cancer screening. JAMA 1996;276:1976-9
28. Snyder PJ. Development of criteria to monitor the occurrence of prostate cancer in testosterone clinical trials. In: Bhasin S, Grabelnick H, Spieler J, Swerdloff R, Wang C, Kelly C, eds. Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley, 1996: 143-50
29. Morgantaler A, Bruning CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904-6
30. Pryor JL. Androgen supplementation causes BPH. In: Bhasin S, Gabelnick H, Spieler J, Swerdloff R, Wang C, Kelly C, eds. Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley, 1996:111-20
31. Meikle W. Discussion: androgen and the prostate. In: Bhasin S, Gabelnick H, Spieler J, Swerdloff R, Wang C, Kelly C, eds. Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley, 1996:115-16
32. Bardin CW. The anabolic action of testosterone. N Engl J Med 1996;335:52-3
33. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1-7
34. Bagatelli C, Bremner W. Androgens in men - uses and abuses. N Engl J Med 1996;334:707-14
35. Reid I, Wattle D, Evans M, Stapleton J. Testosterone therapy in glucocorticoid-treated men. Arch Int Med 1996;156:1173-7
36. Phillips GB, Pinkernell BH, Jing T. The association of hypotestosteronemia with coronary artery disease in men. Aterioscler Thromb 1994;14:701-6
37. Marin P, Holmang S, Jonsson L, et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obesity 1992;16:991-7
38. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092-8
39. Salehian B, Wang C, Alexander G, et al. Pharmocokinetics, bioefficacy and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate. J Clin Endocrinol Metab 1995;80:3567-75
40. Griffin JE, Wilson JD. Disorders of the testes. In: Wilson JD et al. eds. Harrison's Principles of Internal Medicine, Vol. 2. New York: McGraw-Hill, 1994:2006-17
41. Nieschlag E, Behre HM. Pharmacology and clinical uses of testosterone. In: Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. Berlin: Springer-Verlag, 1990: 92-114
42. Bonkovsky HL, Fiellin DA, Smith G, Slaker DP, Simon D, Galambos JT. A randomized controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenternol 1991;86:1200-8
43. Su TP, Pagliaro M, Schmidt P, Pickar D, Wolkowitz O, Rubinow D. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993;269:2760-4
44. Pope HG, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiat 1994;51:375-82
45. Albert DJ, Walsh ML, Jonik RH. Aggression in humans: What is its biological foundations? Neurosci Biobehav Rev 1993;17:405-25
46. Dabbs JM. Testosterone, aggression and delinquency. In: Bhasin S, Gabelnick HL, Spieler J, Swerdloff R, Wang C, Kelly C, eds. Pharmacology, Biology and Clinical Applications of Androgens. New York: Wiley, 1996:179-89
47. Winters SJ. Androgens: endocrine physiology and pharmacology. Anabolic steroid abuse. NIDA Research Monograph Series No. 102, 1990:113-30
48. Bhasin S. Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992;74:1221-5
49. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984;12:469-84
50. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men. J Clin Endocrinol Metab 1996;81:3578-83
51. Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men. J Clin Endocrinol Metab 1996;81:3654-62
52. Phillips WN. Anabolic Reference Guide, 6th issue. Colorado: Mile High Publishing, 1991
53. Rabkin JG, Wagner G, Rabkin R. Testosterone therapy for HIV+ men with and without hypogonadism (submitted, 1997)